ZiP Diagnostics is bringing a sensitivity molecular test for SARS-CoV-2,
to domestic high-volume production.
The ZiP-CoVx test is a point-of-care molecular diagnostic technology that combines its test instruments and assay (swab and cartridge with reagents) manufacturing capacity.
The advantages of this system include:
Direct detection of current SARS-CoV-2 viral infection (not an antibody test).
Sample type includes nasal, nasal-pharyngeal or throat swab with direct insertion into sealed cartridge (saliva sample type in development).
Test result within 15 to 30 minutes with high sensitivity comparable to PCR.
True point-of-care, quickly deploy testing to any location to maximise impact on COVID-19 identification and management.
Low cost test, significantly less than existing laboratory tests (order volume dependant).
Individual test and high throughput cartridge and instrument configurations available.
Site management software provides secure, encrypted records and management of workflow, site administration, sample collection and test instruments.